REFERENCES
  1. Marini C, De Santis F, Sacco S, et al. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results from a Population-Based Study. Stroke . 2005;36(6):1115-1119.
  2. Pistoia F, Sacco S, Tiseo C, et al. The Epidemiology of Atrial Fibrillation and Stroke. Cardiol Clin . 2016;34(2):255-268.
  3. Dries DL, Exner DV, Gersh BJ, et al. Atrial Fibrillation is Associated with an Increased Risk for Mortality and Heart Failure Progression in Patients with Asymptomatic and Symptomatic Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SOLVD Trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol . 1998;32(3):695-703.
  4. Ruddox V, Sandven I, Munkhaugen J, et al. Atrial Fibrillation and the Risk of Myocardial Infarction, All-Cause Mortality and Heart Failure: A Systematic Review and Meta-Analysis. Eur J Prev Cardiol . 2017;24(14):1555-1566.
  5. Turagam MK, Garg J, Whang W, et al. Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Ann Intern Med . 2019;170(1):41-50.
  6. Kuck KH, Furnkranz A, Chun KRJ, et al. Cryoballoon or Radiofrequency Ablation for Symptomatic Paroxysmal Atrial Fibrillation: Reintervention, Rehospitalization, and Quality-of-Life Outcomes in the FIRE AND ICE Trial. Eur Heart J . 2016;37(38):2858-2865.
  7. Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA . 2019;321(13):1275-1285.
  8. Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients with Atrial Fibrillation: The CAPTAF Randomized Controlled Trial. JAMA . 2019;321(11):1059-1068.
  9. Weiner MM, Baron EL, Joshi K, et al. Catheter Versus Surgical Ablation of Atrial Fibrillation: An Analysis of Outcomes. J Cardiothorac Vasc Anesth . 2018;32(5):2435-2443.
  10. Chen C, Zhou X, Zhu M, et al. Catheter Ablation Versus Medical Therapy for Patients with Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis of Evidence from Randomized Controlled Trials.J Interv Card Electrophysiol . 2018;52(1):9-18.
  11. Inohara T, Shrader P, Pieper K, et al. Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA Cardiol . 2018;3(1):54-63.
  12. Margulescu AD, Mont L. Persistent Atrial Fibrillation vs Paroxysmal Atrial Fibrillation: Differences in Management. Expert Rev Cardiovasc Ther . 2017;15(8):601-618.
  13. Darrat YH, Shah J, Elayi C-S, et al. Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial).Am J Cardiol . 2017;119(1):47-51.
  14. Schnabel RB, Yin X, Gona P, et al. 50 Year Trends in Atrial Fibrillation Prevalence, Incidence, Risk Factors, and Mortality in the Framingham Heart Study: A Cohort Study. Lancet . 2015;386(9989):154-162.
  15. Campbell HM, Wehrens XHT. Genetics of Atrial Fibrillation: An Update.Curr Opin Cardiol . 2018;33(3):304-310.
  16. Chalazon B, Mol D, Darbar FA, et al. Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals. JAMA Cardiol . 2021;6(7):811-819.
  17. Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond. Circ Res. 2020;127(1):21-33.
  18. Fatkin D, Santiago CF, Huttner IG, et al. Genetics of Atrial Fibrillation: State of the Art in 2017. Heart Lung Circ . 2017;26(9):894-901.
  19. January CT, Wann S, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.Circulation . 2014;130(23):e199-e267.
  20. Darbar D, Herron KJ, Ballew JD, et al. Familial Atrial Fibrillation is a Genetically Heterogeneous Disorder. J Am Coll Cardiol . 2003;41(12):2185-2192.
  21. Fox CS, Parise H, D’Agostino RB, et al. Parental Atrial Fibrillation as a Risk Factor for Atrial Fibrillation in Offspring. JAMA . 2004;291(23):2851-2855.
  22. Christophersen IE, Ravn LS, Budtz-Joergensen E, et al. Familial Aggregation of Atrial Fibrillation: A Study in Danish Twins.Circ Arrhythm Electrophysiol . 2009;2(4):378-383.
  23. Weng LC, Choi SH, Klarin D, et al. Heritability of Atrial Fibrillation. Circ Cardiovasc Genet . 2017;10(6):e001838.
  24. Postma AV, van der Meerakker JBA, Mathijssen IB, et al. A Gain-of-Function TBX5 Mutation is Associated with Atypical Holt-Oram Syndrome and Paroxysmal Atrial Fibrillation. Circ Res.2008;102(11):1433-1442.
  25. Gudbjartsson DF, Holm H, Sulem P, et al. A Frameshift Deletion in the Sarcomere Gene MYL4 Causes Early-Onset Familial Atrial Fibrillation.Eur Heart J . 2017;38(1):27-34.
  26. Li RG, Xu YJ, Ye WG, et al. Connexin45 (GJC1) Loss-of-Function Mutation Contributes to Familial Atrial Fibrillation and Conduction Disease. Heart Rhythm . 2021;18(5):684-693.
  27. Orr N, Arnaout R, Gula LJ, et al. A Mutation in the Atrial-Specific Myosin Light Chain Gene (MYL4) Causes Familial Atrial Fibrillation.Nat Commun . 2016;7:11303.
  28. Das S, Makino S, Melman YF, et al. A Mutation in the S3 Segment of KCNQ1 Results in Familial Lone Atrial Fibrillation. Heart Rhythm . 2009;6(8):1146-1153.
  29. Roselli C, Chaffin MD, Weng LC, et al. Multi-Ethnic Genome-Wide Association Study for Atrial Fibrillation. Nat Genet . 2018;50(9):1225-1233.
  30. Olesen MS, Andreasen L, Jabbari J, et a. Very Early-Onset Lone Atrial Fibrillation Patients Have a High Prevalence of Rare Variants in Genes Previously Associated with Atrial Fibrillation. Heart Rhythm . 2014;11(2):246-251.
  31. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident Atrial Fibrillation Among Asians, Hispanics, Blacks, and Whites.Circulation . 2013;128(23):2470-2477.
  32. Magnani JW, Norby FL, Agarwal SK, et al. Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiol . 2016;1(4):433-441.
  33. Marcus GM, Olgin JE, Whooley M, et al. Racial Differences in Atrial Fibrillation Prevalence and Left Atrial Size. Am J Med . 2010;123(4):e1-7.
  34. Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-Driven Genomic Discovery Yields New Insight into Atrial Fibrillation Biology.Nat Genet . 2018;50(9):1234-1239.
  35. Song K, Nam YJ, Luo X, et al. Heart Repair by Reprogramming Non-Myocytes with Cardiac Transcription Factors. Nature . 2012;485(7400):599-604.
  36. Lee JY, Kim TH, Yang PS, et al. Korean Atrial Fibrillation Network Genome-Wide Association Study for Early-Onset Atrial Fibrillation Identifies Novel Susceptibility Loci. Eur Heart J . 2017;38(34):2586-2594.
  37. Low SK, Takahaski A, Ebana Y, et al. Identification of Six New Genetic Loci Associated with Atrial Fibrillation in the Japanese Population.Nat Genet . 2017;49(6):953-958.
  38. Chalazan B, Mol D, Sridhar A, et al. Genetic Modulation of Atrial Fibrillation Risk in Hispanic/Latino Cohort. PLoS One . 2018;13(4):e0194480.
  39. Christophersen IE, Rienstra M, Roselli C, et al. Large-Scale Analyses of Common and Rare Variants Identify 12 New Loci Associated with Atrial Fibrillation. Nat Genet . 2017;49(6):946-952.
  40. Chu HM, Feng MJ, Li YG, et al. Polymorphisms but Not Mutations of the KCNQ1 Gene Are Associated with Lone Atrial Fibrillation in the Chinese Han Population. ScientificWorldJournal . 2013;373454.
  41. Wang H, Teng Y, Wang K, et al. The M235T Polymorphism in the Angiotensinogen Gene and Atrial Fibrillation: A Meta-Analysis. J Renin Angiotensin Aldosterone Syst . 2015;16(3):647-652.
  42. Ebana Y, Ozaki K, Liu L, et al. Clinical Utility and Functional Analysis of Variants in Atrial Fibrillation-Associated Locus 4q25.J Cardiol . 2017;70(4):366-373.
  43. Olesen MS, Holst AG, Jabbari J, et al. Genetic Loci on Chromosomes 4q25, 7p31, and 12p12 Are Associated with Lone Atrial Fibrillation Before the Age of 40 Years. Can J Cardiol . 2012;28(2):191-195.
  44. Body SC, Collard CD, Sherman SK, et al. Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. Circ Cardiovasc Genet . 2009;2(5):499-506.
  45. Ryan AK, Blumberg B, Rodriguez-Esteban C, et al. PITX2 Determines Left-Right Asymmetry of Internal Organs in Vertebrates. Nature . 1998;394(6693):545-551.
  46. Bai J, Lu Y, Lo A, et al. PITX2 Upregulation Increases the Risk of Chronic Atrial Fibrillation in a Dose-Dependent Manner By ModulatingIKs and ICaL - Insights from Human Atrial Modelling. Ann Transl Med . 2020;8(5):191.
  47. Lubitz SA, Lunetta KL, Lin H, et al. Novel Genetic Markers Associate with Atrial Fibrillation Risk in Europeans and Japanese. J Am Coll Cardiol . 2014;63(12):1200-1210.
  48. Ritchie MD, Rowan S, Kucera G, et al. Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated with Familial Atrial Fibrillation. J Am Coll Cardiol . 2012;60(13):1173-1181.
  49. Yoneda ZT, Anderson KC, Quintana JA, et al. Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol . 2021;6(12):1371-1379.
  50. Savio-Galimberti E, Darbar D. Atrial Fibrillation and SCN5AVariants. Card Electrophysiol Clin . 2014;6(4):741-748.
  51. Wilde AAM, Amin AS. Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy. JACC Clin Electrophysiol . 2018;4(5):569-579.
  52. McNair WP, Ku L, Taylor MRG, et al. SCN5A Mutation Associated with Dilated Cardiomyopathy, Conduction Disorder, and Arrhythmia.Circulation . 2004;110(15):2163-2167.
  53. Olson TM, Michels VV, Ballew JD, et al. Sodium Channel Mutations and Susceptibility to Heart Failure and Atrial Fibrillation. JAMA . 2005;293(4):447-454.
  54. Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac Sodium Channel (SCN5A ) Variants Associated with Atrial Fibrillation.Circulation . 2008;117(15):1927-1935.
  55. Ilkhanoff L, Arking DE, Lemaitre RN, et al. A Common SCN5A Variant is Associated with PR Interval and Atrial Fibrillation Among African Americans. J Cardiovasc Electrophysiol . 2014;25(11):1150-1157.
  56. Herman DS, Lam L, Taylor MRG, et al. Truncations of Titin Causing Dilated Cardiomyopathy. N Engl J Med . 2012;366(7):619-628.
  57. Corden B, Jarman J, Whiffin N, et al. Association of Titin-Truncating Genetic Variants with Life-Threatening Cardiac Arrhythmias in Patients with Dilated Cardiomyopathy and Implanted Defibrillators. JAMA Netw Open . 2019;2(6):e196520.
  58. Akhtar MM, Lorenzini M, Cicerchia M, et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circ Heart Fail . 2020;13(10):e006832.
  59. Huang K, Trinder M, Roston TM, et al. The Interplay Between Titin, Polygenic Risk, and Modifiable Cardiovascular Risk Factors in Atrial Fibrillation. Can J Cardiol . 2021;37(6):848-856.
  60. Haggerty CM, Damrauer SM, Levin MG, et al. Genomics-First Evaluation of Heart Disease Associated with Titin-Truncating Variants.Circulation . 2019;140(1):42-54.
  61. Ahlberg G, Refsgaard L, Lundegaard PR, et al. Rare Truncating Variants in the Sarcomeric Protein Titin Associate with Familial and Early-Onset Atrial Fibrillation. Nat Commun . 2018;9(1):4316.
  62. Lazarte J, Laksman ZW, Wang J, et al. Enrichment of Loss-of-Function and Copy Number Variants in Ventricular Cardiomyopathy Genes in ‘Lone’ Atrial Fibrillation. Europace . 2021;23(6):844-850.
  63. Choi SH, Weng LC, Roselli C, et al. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation.JAMA . 2018;320(22):2354-2364.
  64. Andreasen L, Bertelsen L, Ghouse J, et al. Early-Onset Atrial Fibrillation Patients Show Reduced Left Ventricular Ejection Fraction and Increased Atrial Fibrosis. Sci Rep . 2020;10:10039.
  65. Khera AV, Chaffin M, Aragam KG, et al. Genome-Wide Polygenic Risk Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations. Nat Genet . 2018;50:1219-1224.
  66. Mars N, Koskela JT, Ripatti P, et al. Polygenic and Clinical Risk Scores and Their Impact on Age at Onset and Prediction of Cardiometabolic Diseases and Common Cancers. Nat Med . 2020;26:549-557.
  67. Weng LC, Preis SR, Hulme OL, et al. Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation.Circulation . 2018;137(10):1027-1038.
  68. Choi SH, Jurgens SJ, Weng LC, et al. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results from a National Biobank. Circ Res. 2020;126(2):200-209.
  69. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm . 2011;8(8):1308-1339.
  70. Ingles J, Macciocca I, Morales A, Thomson K. Genetic Testing in Inherited Heart Diseases. Heart Lung Circ . 2020;29(4):505-511.
  71. Goodyear WR, Dunn K, Caleshu C, et al. Broad Genetic Testing in a Clinical Setting Uncovers a High Prevalence of Titin Loss-of-Function Variants in Very Early Onset Atrial Fibrillation. Circ Genom Precis Med . 2019;12(11):e002713.
  72. Olesen MS, Yuan L, Liang B, et al. High Prevalence of Long QT Syndrome-Associated SCN5A Variants in Patients with Early-Onset Lone Atrial Fibrillation. Circ Cardiovasc Genet . 2012;5(4):450-459.
  73. Brauch KM, Chen LY, Olson TM. Comprehensive Mutation Scanning ofLMNA in 268 Patients with Lone Atrial Fibrillation. Am J Cardiol . 2009;103(10):1426-1428.
  74. Taylor MRG, Fain PR, Sinagra G, et al. Natural History of Dilated Cardiomyopathy Due to Lamin A/C Gene Mutations. J Am Coll Caridol . 2003;41(5):771-780.
  75. Yeung C, Enriquez A, Suarez-Fuster L, Baranchuk A. Atrial Fibrillation in Patients with Inherited Cardiomyopathies. Europace . 2019;21(1):22-32.
  76. Olesen MS, Nielsen MW, Haunsø S, Svendsen JH. Atrial Fibrillation: The Role of Common and Rare Genetic Variants. Eur J Hum Genet . 2014;22(3):297-306.
  77. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy - A Heart Failure Society of America Practice Guideline. J Card Fail . 2018;24(5):281-302.
  78. Chang SH, Kuo CF, Chou IJ, et al. Association of a Family History of Atrial Fibrillation with Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study. JAMA Cardiol . 2017;2(8):863-867.
  79. Alzahrani Z, Ornelas-Loredo A, Darbar SD, et al. Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic Groups. JAMA Netw Open . 2018;1(5):e182497.
  80. Wu Z, Jiang C, Li J, et al. Effect of Family History of Atrial Fibrillation on Recurrence After Atrial Fibrillation Ablation: A Report from the Chinese Atrial Fibrillation Registry Study. J Cardiovasc Electrophysiol . 2021;32(3):678-685.
  81. Heidarali M, Bakhshandeh H, Fazelifar A, Haghjoo M. Clinical Profile and Outcome of Familial Versus Non-Familial Atrial Fibrillation.Int J Cardiol . 2020;314:70-74.
  82. Girolami F, Frisso G, Benelli M, et al. Contemporary Genetic Testing in Inherited Cardiac Disease: Tools, Ethical Issues, and Clinical Applications. J Cardiovasc Med . 2018;19(1):1-11.
  83. Wilson BD, Wasmund SL, Sachse FB, et al. Evidence for a Heritable Contribution to Atrial Fibrillation Associated with Fibrosis.JACC Clin Electrophysiol . 2019;5(4):493-500.
  84. Jessurun ER, van Hemel NM, Defauw JA, et al. Results of Maze Surgery for Lone Paroxysmal Atrial Fibrillation. Circulation . 2000;101(13):1559-1567.
  85. Weimar T, Schena S, Bailey MS, et al. The Cox-Maze Procedure for Lone Atrial Fibrillation: A Single-Center Experience Over 2 Decades.Circ Arrhythm Electrophysiol . 2012;5(1):8-14.
  86. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J . 2021;42(5):373-498.
  87. Barrett TW, Self WH, Darbar D, et al. Association of Atrial Fibrillation Risk Alleles and Response to Acute Rate Control Therapy.Am J Emerg Med . 2016;34(4):735-740.
  88. Parvez B, Vaglio J, Rowan S, et al. Symptomatic Response to Antiarrhythmic Drug Therapy is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. J Am Coll Cardiol . 2012;60(6):539-545.
  89. Wu G, Cheng M, Huang H, et al. A Variant of IL6R is Associated with the Recurrence of Atrial Fibrillation After Catheter Ablation in a Chinese Han Population. PLoS One . 2014;9(6):e99623.
  90. Cao H, Xu W, Chen X, et al. Functional Promoter -1816C>G Variant of RANKL Predicts Risk and Prognosis of Lone Atrial Fibrillation. Heart Vessels . 2019;34(1):151-158.
  91. Choi EK, Park JH, Lee JY, et al. Korean Atrial Fibrillation (AF) Network: Genetic Variants for AF Do Not Predict Ablation Success.J Am Heart Assoc. 2015;4(8):e002046.
  92. Park JK, Lee JY, Yang PS, et al. Good Responders to Catheter Ablation for Long-Standing Persistent Atrial Fibrillation: Clinical and Genetic Characteristics. J Cardiol . 2017;69(3):584-590.
  93. Wu H, Xu J, Chen S, et al. Association of SCN10A Polymorphisms with the Recurrence of Atrial Fibrillation After Catheter Ablation in a Chinese Han Population. Sci Rep . 2017;7:44003.
  94. Ueberham L, Bollmann A, Shoemaker MB, et al. Genetic ACE I/D Polymorphism and Recurrence of Atrial Fibrillation After Catheter Ablation. Circ Arrhythm Electrophysiol. 2013;6(4):732-737.
  95. Zhong Y, Tang K, Li H, et al. Rs4968309 in Myosin Light Chain 4 (MYL4) Associated with Atrial Fibrillation Onset and Predicts Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients Without Structural Heart Disease. Circ J.2019;83(10):1994-2001.
  96. Rahm AK, Lugenbiel P, Ochs M, et al. Pulmonary Vein Isolation Treats Symptomatic AF in a Patient with Lamin A/C Mutation: Case Report and Review of the Literature. Clin Res Cardiol . 2020;109(8):1070-1075.
  97. Wong GR, Nalliah CJ, Lee G, et al. Genetic Susceptibility to Atrial Fibrillation is Associated with Atrial Electrical Remodeling and Adverse Post-Ablation Outcome. JACC Clin Electrophysiol . 2020;6(12):1509-1521.
  98. Shoemaker MB, Muhammad R, Parvez B, et al. Common Atrial Fibrillation Risk Alleles at 4q25 Predict Recurrence After Catheter-Based Atrial Fibrillation Ablation. Heart Rhythm . 2013;10(3):394-400.
  99. Zhao LQ, Zhang GB, Wen ZJ, et al. Common Variants Predict Recurrence After Nonfamilial Atrial Fibrillation Ablation in Chinese Han Population. Int J Cardiol . 2017;227:360-366.
  100. Hu Z, Zou D. Genotype-Phenotype Associations in Atrial Fibrillation: A Meta-Analysis. J Interv Card Electrophysiol . 2019;54(3):283-288.
  101. Ulus T, Dural M, Mese P, et al. Genetic Variants Associated with Atrial Fibrillation and Long-Term Recurrence After Catheter Ablation for Atrial Fibrillation in Turkish Patients. Anatol J Cardiol . 2021;25(2):129-138.
  102. Shoemaker MB, Bollmann A, Lubitz SA, et al. Common Genetic Variants and Response to Atrial Fibrillation Ablation. Circ Arrhythm Electrophysiol . 2015;8(2):296-302.
  103. Husser D, Adams V, Piorkowski C, et al. Chromosome 4q25 and Atrial Fibrillation Recurrence After Catheter Ablation. J Am Coll Cardiol . 2010;55(8):747-753.
  104. He J, Zhu W, Yu Y, et al. Variant rs2200733 and rs10033464 on Chromosome 4q25 Are Associated with Increased Risk of Atrial Fibrillation After Catheter Ablation: Evidence from a Meta-Analysis.Cardiol J . 2018;25(5):628-638.
  105. Choi JI, Baek YS, Roh SY, et al. Chromosome 4q25 Variants and Biomarkers of Myocardial Fibrosis in Patients with Atrial Fibrillation. J Cardiovasc Electrophysiol . 2019;30(10):1904-1913.
  106. Mohanty S, Hall AW, Mohanty P, et al. Novel Association of Polymorphic Genetic Variants with Predictors of Outcome of Catheter Ablation in Atrial Fibrillation: New Directions from a Prospective Study (DECAF).J Interv Card Electrophysiol . 2016;45(1):7-17.
  107. Piccini JP, Connolly SJ, Abraham WT, et al. A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure: Rationale and Design of the GENETIC-AF Trial. Am Heart J . 2018;199:51-58.
  108. Piccini JP, Dufton C, Carroll IA, et al. Bucindolol Decreases Atrial Fibrillation Burden in Patients with Heart Failure and theADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol . 2021;14(8):e009591.
  109. Pison L, Hocini M, Potpara TS, et al. Work-Up and Management of Lone Atrial Fibrillation: Results of the European Heart Rhythm Association Survey. Europace . 2014;16(10):1521-1523.
  110. Kirchhof P, Breithardt G, Bax J, et al. A Roadmap to Improve the Quality of Atrial Fibrillation Management: Proceedings from the Fifth Atrial Fibrillation Network/European Heart Rhythm Association Consensus Conference. Europace . 2016;18(1):37-50.
  111. Hall JL, Barac A, Benjamin EJ. Genetic Mutations as Risk Predictors of Atrial Fibrillation Recurrence After Catheter Ablation? J Am Coll Cardiol . 2010;55(8):754-757.
  112. Lubitz SA, Parsons OE, Anderson CD, et al. Atrial Fibrillation Genetic Risk and Ischemic Stroke Mechanisms. Stroke . 2017;48(6):1451-1456.
  113. Pulit SL, Weng LC, McArdle PF, et al. Atrial Fibrillation Genetic Risk Differentiates Cardioembolic Stroke from Other Stroke Subtypes.Neurol Genet . 2018;4(6):e293.
  114. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. J Am Coll Cardiol . 2016;68(21):2299-2307.
  115. Verdonschot JAJ, Hazebroek MR, Karpels IPC, et al. Implications of Genetic Testing in Dilated Cardiomyopathy. Circ Genom Precis Med . 2020;13(5):476-487.